Clinical Trial

A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Monitoring the Development of Secondary Events in Patients Diagnosed With Traumatic Brain Injury

Recruiting
View on ClinicalTrials.gov →
Summary
The study is intended to cover two purposes: first, to develop a blood-based biomarker test for aiding the diagnosis of traumatic brain injury (TBI) in adult participants and for prognosis of outcome of TBI (CLIN12.1); and second, for monitoring the development of secondary events in adult participants diagnosed with TBI (CLIN12.2).
Protocol Amendment History 2 changes
notable Primary completion pushed: 2028-03-31 -> 2028-09-30 2026-07-29
minor Completion pushed: 2028-05-31 -> 2028-11-23 2026-07-29
Trial Details
NCT Number NCT07455136
Lead Sponsor Hoffmann-La Roche
Collaborators: Roche Diagnostics GmbH
Conditions Traumatic Brain Injury
Enrollment 2,000 participants
Start Date 2026-02-09
Primary Completion 2028-09-30 (estimated)
Study Completion 2028-11-23 (estimated)
Updated on ClinicalTrials.gov 2026-07-28